PCSA · Processa Pharmaceuticals, Inc.
$2.62
-0.25 (-8.71%)
At close · Jul 24
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Absent additional funding, we believe that our cash and cash equivalents, along with our digital assets, will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements are available to be issued.”View the 10-Q filed May 7, 2026
Market Cap
$7.15M
Shares
2.75M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2022
Net Income
$13.56M
+214.5%
FY2025
Gross Margin
100%
+111pp
FY2016
Operating Margin
-38430.4%
FY2016
Diluted EPS
-$10.36
+89.3%
FY2025
Operating Cash Flow
-$11.39M
-1.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | $0 | $0 | — | — | — | — | $5000 | $113.43K | $107.24K | $312.48K | $192.15K | |
| — | — | — | — | — | — | — | — | — | — | — | $125.88K | $66.83K | $188K | $133.26K | |
| — | — | — | — | — | — | — | — | — | — | $5000 | -$12.45K | $40.41K | $124.48K | $58.89K | |
| — | — | — | — | — | — | — | — | — | — | 100% | -10.98% | 37.68% | 39.84% | 30.65% | |
| $8.03M | $7.81M | $7.27M | $5.8M | $11.49M | $6.88M | $3.17M | $2.32M | $3.09M | $964.16K | $1.54M | $29.25K | $178.09K | $267.06K | $448.03K | |
| $6.44M | $6.18M | $4.78M | $5.66M | $8.76M | $4.69M | $3.26M | $1.61M | $1.44M | — | — | — | — | — | — | |
| $1.37M | — | — | — | — | — | — | — | $1.44M | $838.27K | $69.97K | $945.46K | $2.02M | $2.82M | $1.88M | |
| — | — | — | — | $788.5K | $790.49K | $795.33K | $795.33K | $621.65K | — | — | $178.57K | $357.14K | $357.14K | — | |
| — | — | — | — | — | — | — | — | — | $1.8M | $1.92M | $2.68M | $3.41M | $3.09M | $2.33M | |
| -$14.47M | -$13.99M | -$12.05M | -$11.46M | -$27.53M | -$12.13M | -$15.14M | -$3.94M | -$4.52M | -$1.8M | -$1.92M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -38430.4% | — | — | — | — | |
| — | — | — | — | — | $362 | $281.12K | $36.66K | $161.21K | $59.06K | $245.38K | $235.64K | $315.3K | -$109.73K | -$170.72K | |
| — | $109.49K | $201.09K | $335.54K | $101.2K | $11.63K | $3174 | $11.55K | $18.3K | $5181 | $4454 | $4651 | $155 | $2394 | $3131 | |
| — | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.96M | -$15.41M | -$3.96M | -$4.67M | -$1.86M | -$337.18K | -$2.98M | -$3.69M | -$3.07M | -$2.44M | |
| — | — | — | — | — | -$530.61K | -$1M | -$602.72K | -$902.8K | $258.58K | — | -$100 | -$100 | -$50 | -$181 | |
| $13.02M | $13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.43M | -$14.41M | -$3.36M | -$3.77M | -$1.86M | -$1.92M | -$3.35M | -$4.53M | -$3.07M | -$2.44M | |
| — | — | — | — | — | — | — | — | — | — | -38341.32% | -2957.22% | -4220.71% | -982.05% | -1270.15% | |
| -$14.11M | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.43M | -$19.04M | -$3.86M | -$3.77M | — | -$379.04K | -$3.4M | -$6.03M | -$3.09M | -$2.77M | |
| USD/shares | — | -$10.36 | -$96.78 | -$212.00 | -$851.25 | -$375.00 | — | — | — | -$30.00 | -$35.00 | — | — | — | — |
| USD/shares | — | -$10.36 | -$96.78 | -$212.00 | -$851.25 | — | — | — | — | -$30.00 | -$35.00 | — | — | — | — |
| shares | — | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K | 15K | 11.05K | 10.66K | 65.19K | 58.64K | 22.03K | 17.72K | 10.07K | 3686.066 |
| shares | — | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K | 15K | 11.05K | 10.66K | 65.19K | 58.64K | 22.03K | 17.72K | 10.07K | 3686.066 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2015: $88.53K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×